All sounds good JTFM. What a pipeline if this is indeed the case, but this is the game as price quickly erodes for these generics. Bio-equivalence studies means larger market sizes.
While I want to believe that a Libigel resurrection is forthcoming, I am having a hard time footing this with all of the recent executive stock sales. The only scenario I can come up with is that they are freeing up stock for the deal partner(s). Otherwise, there is no deal. Even with all of the attorneys they had working on this, I don't see how the deal would be structured without it positively affecting the ANIP share price. Well, I suppose they could dilute the shares some more to fund the launch. That may be another possible scenario that explains the sales.
News 
Market Data 
Discover 
